SCHEMBL13885180

SCHEMBL13885180

CN(C)Cc1cc(C(=O)c2cccc(NC(=O)Nc3ccc(Cl)cc3Cl)c2)c2c(N)ncnn12

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK2 Q16620 4/20 0.83
▸ NTRK1 P04629 3/20 0.83
▸ EGFR P00533 3/20 0.52
▸ ERBB2 P04626 3/20 0.52
▸ ERBB3 P21860 3/20 0.52
▸ ERBB4 Q15303 3/20 0.52
▸ MAPT P10636 5/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ PDGFRB P09619 1/20 0.45
▸ TEK Q02763 2/20 0.41
▸ KDR P35968 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ AURKA O14965 3/20 0.40
▸ AURKB Q96GD4 3/20 0.40
▸ LMNA P02545 1/20 0.38
▸ HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925304 0.91 NTRK2 (0.79) NTRK2NTRK1EGFRERBB2ERBB3
SCHEMBL1924640 0.91 NTRK2 (1.00) NTRK2NTRK1EGFRERBB2ERBB3
SCHEMBL12537616 0.90 NTRK1 (0.68) NTRK2NTRK1EGFRERBB2ERBB3
SCHEMBL1926089 0.86 NTRK2 (0.72) NTRK2NTRK1EGFRERBB2ERBB3
SCHEMBL13885220 0.86 NTRK2 (0.74) NTRK2NTRK1EGFRERBB2ERBB3
SCHEMBL1925284 0.86 NTRK2 (0.74) NTRK2NTRK1EGFRERBB2ERBB3
SCHEMBL12537229 0.85 NTRK2 (0.71) NTRK2NTRK1EGFRERBB2ERBB3
SCHEMBL1925784 0.85 NTRK2 (0.78) NTRK2NTRK1EGFRERBB2ERBB3
SCHEMBL1925132 0.85 NTRK2 (1.00) NTRK2NTRK1EGFRERBB2ERBB3
SCHEMBL12537234 0.84 NTRK2 (0.69) NTRK2NTRK1EGFRERBB2ERBB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514435-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-07 — — US disclosed
US-20070149534-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-28 — — US disclosed
WO-2007061882-A2 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149534-A1 PYRROLOTRIAZINE KINASE INHIBITORS NTRK2, NTRK3, NTRK1 NTRK2 1/4885NTRK1 3/4885EGFR 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback